Tagged with pharma

GSK Pharma CIS GSK CEO Andrew Witty has said that GSK must move away from selling “white pills in Western markets” in order to offset widespread generic erosion. This means diversifying the company’s portfolio into novel areas and putting greater emphasis on emerging markets. How is the Russian affiliate contributing to the realization…

Ferring Pharmaceuticals SA Representative Office in Romania Ferring is a company with a tremendous history dating back to the 1950s in Sweden. Now present in over 50 countries, the Group has managed to maintain a double digit annual growth over the last 2 decades. Focusing on Romania in particular, can you first of all tell us more…

Biopharmaceutical investments of RVC (RVC BioFund) Biofund is an independent spin-off of the broader Russian Venture Capital organization. What is the working relationship and synergy between these agencies, and what are the market conditions that have necessitated the creation of Biofund? Biofund was created on January 24th, 2011. There are two stakeholders in the creation of…

Bayer Healthcare Pharmaceuticals Russia You were a Russian manager from 1996-2004, departed to Germany for some time, and recently made your way back to Russia in 2010. How has Russian healthcare and industry changed, and what do you find most striking? The biggest difference is the fact that the government is much more involved…

Watson Pharmaceuticals Watson is one the largest generic players in the US but the international presence of the company is still relatively modest. Watson does not have commercial operations in India but you acquired Sekhsaria Chemicals back in 2006, as well as a formulations plant in Goa from Dr Reddy’s. Could you…

Ferring Pharmaceuticals UK Shire’s International Marketing to being COO of start-up medical device company, Medicsight. What about Ferring and your current role attracted you to take this job and what are you bringing on board that is unique from your past experiences? As you mentioned, I have quite an extensive career and would…

Lupin Pharmaceuticals Inc. Two weeks ago, Lupin announced its annual results, portraying 6 years of sustained growth and a net profit up by 27%. How pleased were you with this performance, and were you expecting such strong results? We were pleased, but not very pleased. We thought that we could have done much…

NATCO Pharma Compared to 5 years ago, MNCs have increased their presence in India. Some even have become market leaders, particularly through acquisitions of domestic players. How is this redistributing the game for local players? The Indian market structure is shaped in such way that no generic player gets big market shares.…

MSD pharmaceuticals Pvt. Ltd. While your appointment as Managing Director was not a long time ago, you immediately faced the big task to oversee one of the most complicated corporate mergers the local Indian drug industry has seen in recent years. How challenging was the integration of Fulford and Organon for you? One of…

Pharmaceutical Reearch Institute Would you start by giving our readers a brief outline of the history of the PRI? In 1952 the institute was established as a research and development (R&D) centre for the Polish pharmaceutical industry. In the 1960s the institute became part of what was known as the state-owned “Polfa” consortium…

Emerging Pharma (EP+) Since its origin, Emerging Pharma has been helping foreign pharma companies to enter Malaysia. However, the Malaysian market is relatively small. Why should international pharma companies look to this country as a good first step? It is true that the Malaysian pharmaceutical market is still small at around US$ 1…

Union of Professional Pharmaceutical Organizations (SPFO) Last time Focus Reports met with you in 2006, the Russian pharmaceutical industry had enjoyed five straight years of growth. This growth has since continued through 2011. Can you provide some insight on what has happened in the industry since 2006, and how the market has been able to maintain…